Key result
Antiplatelet therapies, including novel P2Y12 and PAR-1 receptor antagonists, are essential for reducing recurrent atherothrombotic events in patients with cardiovascular disease.
Design
Review
Authors
Loading...
Reinforces antiplatelet strategies in CVD prevention; leaves open optimal selection of novel antagonists pending higher-level trials.
This review highlights the mechanisms of platelet activation in atherothrombosis and the ongoing development of novel antiplatelet therapies to balance ischemic risk reduction with bleeding safety.
Ueno et al. (2011) conducted a review in Cardiovascular Disease. Antiplatelet Therapy was evaluated. Antiplatelet therapies, including novel P2Y12 and PAR-1 receptor antagonists, are essential for reducing recurrent atherothrombotic events in patients with cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: